Diéssica Padilha Dalenogare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diéssica Padilha Dalenogare has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Francesco De Logu
Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy
2 shared publications - Gabriela Trevisan
Graduate Program in Pharmacology, Federal University of Santa Maria (UFSM), Santa Maria 97105-900, Brazil
2 shared publications - Lorenzo Landini
Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy
2 shared publications - Pierangelo Geppetti
Department of Molecular Pathobiology, Pain Research Center, College of Dentistry New York University New York New York USA
2 shared publications - Romina Nassini
Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy
2 shared publications - Andréia Machado Cardoso
Graduate Program in Biomedical Sciences Federal University of Fronteira Sul, Campus Chapecó Chapecó Santa Catarina Brazil
1 shared publication
Latest Publications
- Open Access
Neuropathic-like Nociception and Spinal Cord Neuroinflammation Are Dependent on the TRPA1 Channel in Multiple Sclerosis Models in Mice
Background: Transient receptor potential ankyrin 1 (TRPA1) activation is implicated in neuropathic pain-like symptoms. However, whether TRPA1 is solely implicated in pain-signaling or contributes to neuroinflammation in multiple sclerosis (MS) is unknown. Here, we evaluated the TRPA1 role in neuroinflammation underlying pain-like symptoms using two different models of MS. Methods: Using a myelin antigen, Trpa1+/+ or Trpa1−/− female mice developed relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) (Quil A as adjuvant) or progressive experimental autoimmune encephalomyelitis (PMS)-EAE (complete Freund’s adjuvant). The locomotor performance, clinical scores, mechanical/cold allodynia, and neuroinflammatory MS markers were evaluated. Results: Mechanical and cold allodynia detected in RR-EAE, or PMS-EAE Trpa1+/+ mice, were not observed in Trpa1−/− mice. The increased number of cells labeled for ionized calcium-binding adapter molecule 1 (Iba1) or glial fibrillary acidic protein (GFAP), two neuroinflammatory markers in the spinal cord observed in both RR-EAE or PMS-EAE Trpa1+/+ mice, was reduced in Trpa1−/− mice. By Olig2 marker and luxol fast blue staining, prevention of the demyelinating process in Trpa1−/− induced mice was also detected. Conclusions: Present results indicate that the proalgesic role of TRPA1 in EAE mouse models is primarily mediated by its ability to promote spinal neuroinflammation and further strengthen the channel inhibition to treat neuropathic pain in MS.
Open AccessNeuropathic-like Nociception and Spinal Cord Neuroinflammation Are Dependent on the TRPA1 Channel in Multiple Sclerosis Models in Mice
Background: Transient receptor potential ankyrin 1 (TRPA1) activation is implicated in neuropathic pain-like symptoms. However, whether TRPA1 is solely implicated in pain-signaling or contributes to neuroinflammation in multiple sclerosis (MS) is unknown. Here, we evaluated the TRPA1 role in neuroinflammation underlying pain-like symptoms using two different models of MS. Methods: Using a myelin antigen, Trpa1+/+ or Trpa1−/− female mice developed relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) (Quil A as adjuvant) or progressive experimental autoimmune encephalomyelitis (PMS)-EAE (complete Freund’s adjuvant). The locomotor performance, clinical scores, mechanical/cold allodynia, and neuroinflammatory MS markers were evaluated. Results: Mechanical and cold allodynia detected in RR-EAE, or PMS-EAE Trpa1+/+ mice, were not observed in Trpa1−/− mice. The increased number of cells labeled for ionized calcium-binding adapter molecule 1 (Iba1) or glial fibrillary acidic protein (GFAP), two neuroinflammatory markers in the spinal cord observed in both RR-EAE or PMS-EAE Trpa1+/+ mice, was reduced in Trpa1−/− mice. By Olig2 marker and luxol fast blue staining, prevention of the demyelinating process in Trpa1−/− induced mice was also detected. Conclusions: Present results indicate that the proalgesic role of TRPA1 in EAE mouse models is primarily mediated by its ability to promote spinal neuroinflammation and further strengthen the channel inhibition to treat neuropathic pain in MS.
- Open Access
- 23 August 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 831
Periorbital Nociception in a Progressive Multiple Sclerosis Mouse Model Is Dependent on TRPA1 Channel Activation
Headaches are frequently described in progressive multiple sclerosis (PMS) patients, but their mechanism remains unknown. Transient receptor potential ankyrin 1 (TRPA1) was involved in neuropathic nociception in a model of PMS induced by experimental autoimmune encephalomyelitis (PMS-EAE), and TRPA1 activation causes periorbital and facial nociception. Thus, our purpose was to observe the development of periorbital mechanical allodynia (PMA) in a PMS-EAE model and evaluate the role of TRPA1 in periorbital nociception. Female PMS-EAE mice elicited PMA from day 7 to 14 days after induction. The antimigraine agents olcegepant and sumatriptan were able to reduce PMA. The PMA was diminished by the TRPA1 antagonists HC-030031, A-967079, metamizole and propyphenazone and was absent in TRPA1-deficient mice. Enhanced levels of TRPA1 endogenous agonists and NADPH oxidase activity were detected in the trigeminal ganglion of PMS-EAE mice. The administration of the anti-oxidants apocynin (an NADPH oxidase inhibitor) or alpha-lipoic acid (a sequestrant of reactive oxygen species), resulted in PMA reduction. These results suggest that generation of TRPA1 endogenous agonists in the PMS-EAE mouse model may sensitise TRPA1 in trigeminal nociceptors to elicit PMA. Thus, this ion channel could be a potential therapeutic target for the treatment of headache in PMS patients.
- 23 August 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 831
Open AccessPeriorbital Nociception in a Progressive Multiple Sclerosis Mouse Model Is Dependent on TRPA1 Channel Activation
Headaches are frequently described in progressive multiple sclerosis (PMS) patients, but their mechanism remains unknown. Transient receptor potential ankyrin 1 (TRPA1) was involved in neuropathic nociception in a model of PMS induced by experimental autoimmune encephalomyelitis (PMS-EAE), and TRPA1 activation causes periorbital and facial nociception. Thus, our purpose was to observe the development of periorbital mechanical allodynia (PMA) in a PMS-EAE model and evaluate the role of TRPA1 in periorbital nociception. Female PMS-EAE mice elicited PMA from day 7 to 14 days after induction. The antimigraine agents olcegepant and sumatriptan were able to reduce PMA. The PMA was diminished by the TRPA1 antagonists HC-030031, A-967079, metamizole and propyphenazone and was absent in TRPA1-deficient mice. Enhanced levels of TRPA1 endogenous agonists and NADPH oxidase activity were detected in the trigeminal ganglion of PMS-EAE mice. The administration of the anti-oxidants apocynin (an NADPH oxidase inhibitor) or alpha-lipoic acid (a sequestrant of reactive oxygen species), resulted in PMA reduction. These results suggest that generation of TRPA1 endogenous agonists in the PMS-EAE mouse model may sensitise TRPA1 in trigeminal nociceptors to elicit PMA. Thus, this ion channel could be a potential therapeutic target for the treatment of headache in PMS patients.
- 17 April 2015
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 405 (1-2) , 11-21
Vitamin D3 prevents the increase in ectonucleotidase activities and ameliorates lipid profile in type 1 diabetic rats
This study was designed to assess the potential effect of vitamin D3 (VD3) in avoiding atherothrombosis by modulation of lipid metabolism and platelet activation in type 1 diabetic rats. Male wistar rats were divided into eight groups (n = 5–10): Control/Saline (Sal); Control/Metformin 500 mg/kg (Metf); Control/Vitamin D3 90 µg/kg (VD3); Control/Metformin 500 mg/kg + VD3 90 µg/kg (Metf + VD3); Diabetic/Saline (Sal); Diabetic/Metformin 500 mg/kg (Metf); Diabetic/Vitamin D3 90 µg/kg (VD3); Diabetic/Metformin 500 mg/kg + VD3 90 µg/kg (Metf + VD3). Treatments were administered during 30 days after diabetes induction with streptozotocin (STZ). After 31 days, the rats were euthanized and blood was collected and separated into serum and platelets, both used for lipid profile and ectonucleotidase activity assays, respectively. Ectonucleoside triphosphate phosphohydrolase (E-NTPDase), ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP), and 5′-nucleotidase and adenosine deaminase (E-ADA) were significantly higher in the Diabetic than in Control group. Treatment with Metf and/or VD3 prevented the increase in NTPDase and E-NPP activities in diabetic rats. Only Metf + VD3 significantly prevented the increase in 5′-nucleotidase. VD3 alone, but not Metf, prevented the increase in ADA activity when compared to saline-treated diabetic rats. Treatment of rats with VD3, Metf, and Metf + VD3 was also effective in the prevention of lipid metabolism disorder in diabetic and was able to ameliorate lipid metabolism in non-diabetic rats. These results provide evidence for the potential of Metf and VD3 in the treatment of platelet dysfunction and lipid metabolism impairment in T1D, which may be important in the control and prevention of atherothrombosis in diabetes.
- 17 April 2015
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 405 (1-2) , 11-21
Vitamin D3 prevents the increase in ectonucleotidase activities and ameliorates lipid profile in type 1 diabetic rats
This study was designed to assess the potential effect of vitamin D3 (VD3) in avoiding atherothrombosis by modulation of lipid metabolism and platelet activation in type 1 diabetic rats. Male wistar rats were divided into eight groups (n = 5–10): Control/Saline (Sal); Control/Metformin 500 mg/kg (Metf); Control/Vitamin D3 90 µg/kg (VD3); Control/Metformin 500 mg/kg + VD3 90 µg/kg (Metf + VD3); Diabetic/Saline (Sal); Diabetic/Metformin 500 mg/kg (Metf); Diabetic/Vitamin D3 90 µg/kg (VD3); Diabetic/Metformin 500 mg/kg + VD3 90 µg/kg (Metf + VD3). Treatments were administered during 30 days after diabetes induction with streptozotocin (STZ). After 31 days, the rats were euthanized and blood was collected and separated into serum and platelets, both used for lipid profile and ectonucleotidase activity assays, respectively. Ectonucleoside triphosphate phosphohydrolase (E-NTPDase), ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP), and 5′-nucleotidase and adenosine deaminase (E-ADA) were significantly higher in the Diabetic than in Control group. Treatment with Metf and/or VD3 prevented the increase in NTPDase and E-NPP activities in diabetic rats. Only Metf + VD3 significantly prevented the increase in 5′-nucleotidase. VD3 alone, but not Metf, prevented the increase in ADA activity when compared to saline-treated diabetic rats. Treatment of rats with VD3, Metf, and Metf + VD3 was also effective in the prevention of lipid metabolism disorder in diabetic and was able to ameliorate lipid metabolism in non-diabetic rats. These results provide evidence for the potential of Metf and VD3 in the treatment of platelet dysfunction and lipid metabolism impairment in T1D, which may be important in the control and prevention of atherothrombosis in diabetes.